Coexistence of systemic lupus erythematosus and multiple sclerosis: Prevalence, clinical characteristics, and natural history

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 6, 2014, Pages 751-758

  Fanouriakis, Antonis ^a   Mastorodemos, Vasileios ^a   Pamfil, Cristina ^b   Papadaki, Efrosini ^a   Sidiropoulos, Prodromos ^a   Plaitakis, Andreas ^a   Amoiridis, George ^a   Bertsias, George ^a,c   Boumpas, Dimitrios T ^a,c,d  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c INSTITUTE OF COMPUTER SCIENCE   (Greece)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Coexistence; Multiple sclerosis; Natural history; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CARBAMAZEPINE; CORTICOSTEROID; CORTICOTROPIN; HYDROXYCHLOROQUINE; METHOTREXATE; PROPANTHELINE BROMIDE; STEROID; ANTIRHEUMATIC AGENT; GLATIRAMER; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NATALIZUMAB; PEPTIDE; RITUXIMAB;

ADULT; ARTICLE; CLINICAL DECISION MAKING; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; URTICARIA; COMORBIDITY; GREECE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; COMORBIDITY; FEMALE; GREECE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHOTREXATE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; PREVALENCE;

EID: 84902551533     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.11.007     Document Type: Article

References (46)

1. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
2. Bertsias G.K., Boumpas D.T. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010, 6:358-367.
3. McCombe P.A., Chalk J.B., Pender M.P. Familial occurrence of multiple sclerosis with thyroid disease and systemic lupus erythematosus. J Neurol Sci 1990, 97:163-171.
4. Kinnunen E., Muller K., Keto P., Ketonen L., Helve T., Sepponen R. Cerebrospinal fluid and MRI findings in three patients with multiple sclerosis and systemic lupus erythematosus. Acta Neurol Scand 1993, 87:356-360.
5. Hietaharju A., Peltola J., Seppa J., Luukkainen R., Dastidar P. The coexistence of systemic lupus erythematosus and multiple sclerosis in a mother and daughter. Scand J Rheumatol 2001, 30:120-122.
6. Kyrozis A., Kararizou E., Georgila E., Loukaidis P.N., Koureas A., Rombos A., et al. Rare association of multiple sclerosis and systemic lupus erythematosus. Lupus 2007, 16:991-992.
7. Banerjee S., Kumar L., Singh S., Kakkar N. Multiple sclerosis and systemic lupus erythematosus in a 10-year-old girl. Indian Pediatr 1997, 34:159-162.
8. Tola M.R., Casetta I., Granieri E., Caniatti L.M., Monetti V.C., Pascarella R. Systemic lupus erythematosus related recurrent transverse myelitis in a patient with myasthenia gravis and multiple sclerosis. Eur Neurol 1996, 36:327-328.
9. Berk M.A., Sloan J.B., Fretzin D.F. Lupus erythematosus in a patient with long-standing multiple sclerosis. J Am Acad Dermatol 1988, 19:969-972.
10. Langer-Gould A., Albers K.B., Van Den Eeden S.K., Nelson L.M. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler 2010, 16:855-861.
11. Kang J.H., Chen Y.H., Lin H.C. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol 2010, 17:1215-1219.
12. Ramagopalan S.V., Dyment D.A., Valdar W., Herrera B.M., Criscuoli M., Yee I.M., et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007, 6:604-610.
13. Henderson R.D., Bain C.J., Pender M.P. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci 2000, 7:434-437.
14. Nielsen N.M., Frisch M., Rostgaard K., Wohlfahrt J., Hjalgrim H., Koch-Henriksen N., et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler 2008, 14:823-829.
15. Kotzamani D., Panou T., Mastorodemos V., Tzagournissakis M., Nikolakaki H., Spanaki C., et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology 2012, 78:1728-1735.
16. Vazgiourakis V.M., Zervou M.I., Choulaki C., Bertsias G., Melissourgaki M., Yilmaz N., et al. A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. Ann Rheum Dis 2011, 70:2184-2190.
17. Bertsias G.K., Nakou M., Choulaki C., Raptopoulou A., Papadimitraki E., Goulielmos G., et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 2009, 60:207-218.
18. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
19. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
20. Petri M., Orbai A.M., Alarcon G.S., Gordon C., Merrill J.T., Fortin P.R., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64:2677-2686.
21. Mastorodemos V., Nikolakaki H., Tzagournissakis M., Kotzamani D., Panou T., Spanaki C., et al. Benign multiple sclerosis in Crete. Mult Scler 2010, 16:701-706.
22. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
23. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
24. Keiserman B., da Silva L.F., Keiserman M.W., von Muhlen C.A., Staub H.L. Lupoid sclerosis. Rheumatol Int 2010, 30:431-434.
25. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42:599-608.
26. Dobson R., Giovannoni G. Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. J Neurol 2013, 260(5):1272-1285.
27. Sawcer S., Hellenthal G., Pirinen M., Spencer C.C., Patsopoulos N.A., Moutsianas L., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
28. Gateva V., Sandling J.K., Hom G., Taylor K.E., Chung S.A., Sun X., et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009, 41:1228-1233.
29. Richard-Miceli C., Criswell L.A. Emerging patterns of genetic overlap across autoimmune disorders. Genome Med 2012, 4:6.
30. Ramos P.S., Criswell L.A., Moser K.L., Comeau M.E., Williams A.H., Pajewski N.M., et al. A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap. PLoS Genet 2011, 7:e1002406.
31. Mandel M., Gurevich M., Pauzner R., Kaminski N., Achiron A. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol 2004, 138:164-170.
32. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723.
33. Nakou M., Knowlton N., Frank M.B., Bertsias G., Osban J., Sandel C.E., et al. Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. Arthritis Rheum 2008, 58:3541-3549.
34. Ottoboni L., Keenan B.T., Tamayo P., Kuchroo M., Mesirov J.P., Buckle G.J., et al. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med 2012, 4. [153ra31].
35. Nacionales D.C., Kelly-Scumpia K.M., Lee P.Y., Weinstein J.S., Lyons R., Sobel E., et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 2007, 56:3770-3783.
36. Axtell R.C., Raman C. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 2012, 248:23-35.
37. Crispin J.C., Diaz-Jouanen E. Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis. Lupus 2005, 14:495-496.
38. Palace J., Leite M.I., Nairne A., Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010, 67:1016-1017.
39. Pittock S.J., Lennon V.A., de Seze J., Vermersch P., Homburger H.A., Wingerchuk D.M., et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008, 65:78-83.
40. Birnbaum J., Kerr D. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008, 4:381-386.
41. Feng X., Reder N.P., Yanamandala M., Hill A., Franek B.S., Niewold T.B., et al. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci 2012, 313:48-53.
42. Roussel V., Yi F., Jauberteau M.O., Couderq C., Lacombe C., Michelet V., et al. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun 2000, 14:259-265.
43. Sastre-Garriga J., Reverter J.C., Font J., Tintore M., Espinosa G., Montalban X. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol 2001, 49:408-411.
44. Rodrigues C.E., Carvalho J.F., Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest 2010, 40:350-359.
45. Cuadrado M.J., Khamashta M.A., Ballesteros A., Godfrey T., Simon M.J., Hughes G.R. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000, 79:57-68.
46. Ferreira S., D'Cruz D.P., Hughes G.R. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?. Rheumatology (Oxford) 2005, 44:434-442.